Risks and Clinical Predictors of Hepatocellular Carcinoma in Chinese Populations: A Real-World Study of 10,359 Patients in Six Medical Centers
Chenjun Huang,Xiao Xiao,Lin Tong,Zhiyuan Gao,Jun Ji,Lin Zhou,Ya Li,Lijuan Liu,Huijuan Feng,Meng Fang,Chunfang Gao
DOI: https://doi.org/10.2147/jhc.s447700
2024-02-28
Journal of Hepatocellular Carcinoma
Abstract:Chenjun Huang, 1, &ast Xiao Xiao, 1, &ast Lin Tong, 2, &ast Zhiyuan Gao, 1 Jun Ji, 2 Lin Zhou, 3 Ya Li, 4 Lijuan Liu, 5 Huijuan Feng, 5 Meng Fang, 2 Chunfang Gao 1, 2 1 Department of Clinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, People's Republic of China; 2 Department of Laboratory Medicine, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People's Republic of China; 3 Department of Laboratory Medicine, Shanghai Changzheng Hospital, Shanghai, 200003, People's Republic of China; 4 Department of Laboratory Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, 650032, People's Republic of China; 5 Department of Laboratory Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, People's Republic of China &astThese authors contributed equally to this work Correspondence: Chunfang Gao, Department of Clinical Laboratory Medicine Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, People's Republic of China, Tel +86-21-65161782-1210, Email ; Purpose: Early detection of hepatocellular carcinoma (HCC) through surveillance could reduce this cancer-associated mortality. We aimed to develop and validate algorithms using panel serum biomarkers to identify HCC in a real-world multi-center study in China. Patients and Methods: A total of 10,359 eligible subjects, including HCCs and benign liver diseases (BLDs), were recruited from six Chinese medical centers. The three nomograms were built using logistic regression and their sensitivities and specificities were carefully assessed in training and validation cohorts. HCC patients after surgical resection were followed to determine the prognostic values of these algorithms. Prospective surveillance performance was assessed in a cohort of chronic hepatitis B patients during 144 weeks follow-up. Results: Independent risk factors such as alpha-fetoprotein (AFP), lens cuinaris agglutinin-reactive fraction of AFP (AFP-L3), des-gamma-carboxy prothrombin (DCP), albumin (ALB), and total bilirubin (TBIL) obtained from train cohort were used to construct three nomograms (LAD, C-GALAD, and TAGALAD) using logistic regression. In the training and two validation cohorts, their AUCs were all over 0.900, and the higher AUCs appeared in TAGALAD and C-GALAD. Furthermore, the three nomograms could effectively stratify HCC into two groups with different survival and recurrence outcomes in follow-up validation. Notably, TAGALAD could predict HCC up to 48 weeks (AUC: 0.984) and 24 weeks (AUC: 0.900) before clinical diagnosis. Conclusion: The proposed nomograms generated from real-world Chinese populations are effective and easy-to use for HCC surveillance, diagnosis, as well as prognostic evaluation in various clinical scenarios based on data feasibility. Keywords: hepatocellular carcinoma, real-world data, diagnostic, prognosis, algorithm Hepatocellular carcinoma (HCC) is a growing public health problem and the third leading cause of cancer mortality worldwide, 1 about half of which occur in China. 2 Chronic hepatitis B virus (HBV) infection is closely associated with the development of HCC in China. 3 The lack of surveillance and early diagnosis tools is blamed for the poor prognosis and high mortality of HCC. 4,5 The imaging technology [such as computed tomography (CT) and ultrasonography (US)], together with serum α-fetoprotein (AFP), has been recommended by clinical guidelines for the screening of HCC. 6 However, ultrasonography screening has been challenged when distinguishing small HCC from cirrhosis with an accuracy ranging from 47% to 63%. 7,8 Similarly, the serum AFP as a vital tumor marker for HCC is elevated to varying degrees compared to healthy negative controls, and sensitivity is limited to 65%. 7 Therefore, there is an unmet need for a single serum marker in detecting early-stage HCC. As the amount of available high-throughput clinical data in medical centers continues to grow, an open question has arisen, ie how to make appropriate use of these large-scale data to achieve a comprehensive identification of cancer. Machine learning algorithms are powerful scientific mathematical tools and have provided valuable early diagnosis and prognosis evaluation methods for several human diseases. 9 R -Abstract Truncated-
oncology